TY - JOUR T1 - A Phase 2 study of cisplatin analog CI-973 in the treatment of patients with refractory, advanced ovarian cancer JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 257 LP - 260 DO - 10.1136/ijgc-00009577-199607000-00002 VL - 6 IS - 4 AU - J.A. Roberts AU - A. P. Kudelka AU - D. R. Spriggs AU - F. Muggia AU - J. Lurain AU - W. Grove AU - C. Kowal Y1 - 1996/07/01 UR - http://ijgc.bmj.com/content/6/4/257.abstract N2 - The platinum analog CI-973 was selected for clinical study because it is associated with fewer and milder toxicities than either cisplatin or carboplatin in experimental animals, and because it has activity against cisplatin-resistant cell lines in vitro. In this Phase 2 study, 31 women with platinum-resistant or recurrent ovarian carcinoma were treated with CI-973. Three patients achieved a complete response, defined as the disappearance of all measurable disease. The median Kaplan-Meier survival time was estimated to be approximately 7 months from the start of treatment. The most frequently occurring drug-related toxicities were neutropenia, nausea, vomiting, asthenia, anemia, abdominal pain, and diarrhea. Most toxicities were mild or moderate and none resulted in withdrawal from treatment. Despite this favorable toxicity profile, the low response rate of 10% does not support further clinical development of CI-973 as treatment for ovarian cancer. ER -